| Browse All

Crescent Biopharma, Inc. (CBIO)

Healthcare | Biotechnology | Waltham, United States | NasdaqCM
24.57 USD +2.88 (13.278%) ⇧ (April 21, 2026, 4 p.m. EDT)

Short-term:★★★☆☆Long-term:★☆☆☆☆Dividends:★☆☆☆☆
Hot Take | April 19, 2026, 12:21 a.m. EDT

Despite exceptionally strong short-term momentum (86% weekly surge, strong buy analyst consensus, and massive capital raise for R&D), the long-term outlook is bearish due to unprofitability and negative free cash flow, while the nonexistent dividend history reflects the company's high-risk, biotech nature.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.203223
AutoETS0.204429
AutoARIMA0.204430
AutoTheta0.226389

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 45%
H-stat 7.94
Ljung-Box p 0.000
Jarque-Bera p 0.062
Excess Kurtosis -1.01
Attribute Value
Sector Healthcare
Last Dividend Date 2023-01-12
Debt to Equity Ratio 0.81
Revenue per Share 0.903
Market Cap 748,077,056
Forward P/E -6.87
Website https://crescentbiopharma.com

Dividend Data

Dividend History
Date Dividend Yield %
2023-01-13 24.0 7.947020
2022-09-21 143.0 243.749995
Additional Data
trailingAnnualDividendRate 0.0
trailingAnnualDividendYield 0.0
lastDividendValue 24.0
lastDividendDate 2023-01-13

Info Dump

Attribute Value
52 Week Change 0.023749948
Address1 300 Fifth Avenue
All Time High 2,605.0
All Time Low 8.72
Ask 24.74
Ask Size 1
Average Analyst Rating 1.1 - Strong Buy
Average Daily Volume10 Day 250,310
Average Daily Volume3 Month 223,180
Average Volume 223,180
Average Volume10Days 250,310
Bid 24.26
Bid Size 1
Book Value 5.992
City Waltham
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 24.57
Current Ratio 6.561
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 24.7
Day Low 20.4
Debt To Equity 0.81
Display Name Crescent Biopharma
Ebitda -152,548,000
Ebitda Margins 0.0
Enterprise To Ebitda -3.989
Enterprise To Revenue 56.116
Enterprise Value 608,517,248
Eps Current Year -3.48667
Eps Forward -3.57667
Eps Trailing Twelve Months -12.81
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 13.9058
Fifty Day Average Change 10.6642
Fifty Day Average Change Percent 0.7668886
Fifty Two Week Change Percent 2.3749948
Fifty Two Week High 29.0
Fifty Two Week High Change -4.4300003
Fifty Two Week High Change Percent -0.15275863
Fifty Two Week Low 8.72
Fifty Two Week Low Change 15.849999
Fifty Two Week Low Change Percent 1.8176605
Fifty Two Week Range 8.72 - 29.0
Financial Currency USD
First Trade Date Milliseconds 1,389,364,200,000
Float Shares 14,421,470
Forward Eps -3.57667
Forward P E -6.8695183
Free Cashflow -153,697,632
Full Exchange Name NasdaqCM
Full Time Employees 44
Gmt Off Set Milliseconds -14,400,000
Gross Margins 1.0
Gross Profits 10,844,000
Has Pre Post Market Data 1
Held Percent Insiders 0.05817
Held Percent Institutions 0.87571996
Implied Shares Outstanding 30,446,767
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Language en-US
Last Dividend Date 1,673,568,000
Last Dividend Value 24.0
Last Fiscal Year End 1,767,139,200
Last Split Date 1,750,032,000
Last Split Factor 1:100
Long Business Summary Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Long Name Crescent Biopharma, Inc.
Market us_market
Market Cap 748,077,056
Market State PRE
Max Age 86,400
Message Board Id finmb_1902132924
Most Recent Quarter 1,767,139,200
Net Income To Common -153,942,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 747,468,129
Number Of Analyst Opinions 7
Open 21.53
Operating Cashflow -71,532,000
Operating Margins -8.43711
Payout Ratio 0.0
Phone 617 460 5595
Previous Close 21.69
Price Eps Current Year -7.0468383
Price Hint 2
Price To Book 4.100467
Price To Sales Trailing12 Months 68.985344
Profit Margins 0.0
Quick Ratio 6.409
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.11111
Region US
Regular Market Change 2.88
Regular Market Change Percent 13.278
Regular Market Day High 24.7
Regular Market Day Low 20.4
Regular Market Day Range 20.4 - 24.7
Regular Market Open 21.53
Regular Market Previous Close 21.69
Regular Market Price 24.57
Regular Market Time 1,776,801,601
Regular Market Volume 543,077
Return On Assets -0.69149
Return On Equity -1.6074699
Revenue Per Share 0.903
Sand P52 Week Change 0.3140242
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 27,556,767
Shares Percent Shares Out 0.0735
Shares Short 2,238,781
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 1,445,957
Short Name Crescent Biopharma, Inc.
Short Percent Of Float 0.1855
Short Ratio 10.93
Source Interval 15
State MA
Symbol CBIO
Target High Price 35.0
Target Low Price 22.0
Target Mean Price 29.28571
Target Median Price 29.0
Total Cash 213,192,000
Total Cash Per Share 6.419
Total Debt 1,644,000
Total Revenue 10,844,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -12.81
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 12.9716
Two Hundred Day Average Change 11.5984
Two Hundred Day Average Change Percent 0.894138
Type Disp Equity
Volume 543,077
Website https://crescentbiopharma.com
Zip 2,451